胸腺素治疗小儿哮喘免疫状态研究

为了探讨哮喘的免疫机制及防治措施,本文对50名哮喘患儿进行了临床免疫学研究,检测胸腺素治疗后ERFC、LTT效价结合临床改善情况作为判定胸腺素对哮喘患儿体内细胞免疫状态影响的指标。结果表明:哮喘组ERFC和LTT百分率显著低于健康对照组,体外胸腺素激活ERFC明显提高(P<0.001),胸腺素治疗后,患儿ERFC、LTT明显增高,与正常儿童无差别,哮喘组体外胸腺素激活ERFC增加率与胸腺素治疗后ERFC增加率呈高度正相关(r=0.9226)。支气管哮喘应用免疫调节剂是合理的。

STUDY ON INFANTILE ASTHMATIC IMMUNE STATUS WITH THYMOSIN TREATMENT

50 asthmatie children have been studied with the clinical immunology to explore the immune mechanism and the preventive methods of asthma. The percentage of ERFC and LTT after treatment with thymosin and the clinic improvement of asthmatic children's cellular immune status in vivo inferenced by thymosin are established as the criteria. The results show that there are significant low in the percentage of ERFC and LTT in asthmntic group which compared with the control group. There is no difference between the percentage of ERFC and LTT in asthmatic children treated with thymosin and that in the controls. A ratio between the percentage of ERFC actived by thymosin in vitro and that treated by thymosin in vivo is found (r=0.9226), Therefore the use of immnne regulators in the treatment of asthma is reasonable.